The global interleukin inhibitors market size is expected to reach USD 74.6 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 17.4% over the forecast period. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.
The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB’s bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.
Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.
Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn’s & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).
Request a sample Copy of the Interleukin Inhibitors Market Research Report @ https://www.grandviewresearch.com/industry-analysis/interleukin-inhibitors-market/request/rs1
Key Takeways Of The Report :
- Psoriatic arthritis and IBD are projected to register fastest growth through to 2026
- IL-17 is likely to overtake IL-23 as the leading type by 2026
- IL-5 inhibitors for asthma to witness strong growth in the near future
- Asia Pacific is expected to exhibit the fastest regional growth
- Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration
Have Any Query? Ask Our Experts @ https://www.grandviewresearch.com/inquiry/6099/ib
Grand View Research has segmented the global interleukin inhibitors market based on application, type, and region:
Interleukin Inhibitors Application Outlook (Revenue, USD Million, 2014 – 2026)
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Inflammatory Bowel Disease
Interleukin Inhibitors Type Outlook (Revenue, USD Million, 2014 – 2026)
Interleukin InhibitorsRegional Outlook (Revenue, USD Million, 2014 – 2026)
- North America
- Asia Pacific
- South Korea
- Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
Browse Related Report:
Atrial Fibrillation Market : https://www.grandviewresearch.com/industry-analysis/atrial-fibrillation-treatment-industry
CIS Insulin Market : https://www.grandviewresearch.com/industry-analysis/cis-insulin-market
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
Country: United States